Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis

被引：0

作者：

James Yarmolinsky

Emmanouil Bouras

Andrei Constantinescu

Kimberley Burrows

Caroline J. Bull

Emma E. Vincent

Richard M. Martin

Olympia Dimopoulou

Sarah J. Lewis

Victor Moreno

Marijana Vujkovic

Kyong-Mi Chang

Benjamin F. Voight

Philip S. Tsao

Marc J. Gunter

Jochen Hampe

Andrew J. Pellatt

Paul D. P. Pharoah

Robert E. Schoen

Steven Gallinger

Mark A. Jenkins

Rish K. Pai

Dipender Gill

Kostas K. Tsilidis

机构：

[1] University of Bristol,MRC Integrative Epidemiology Unit

[2] Bristol Medical School,Population Health Sciences

[3] University of Bristol,Department of Hygiene and Epidemiology

[4] University of Ioannina Medical School,School of Translational Health Sciences

[5] University of Bristol,NIHR Bristol Biomedical Research Centre

[6] University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol,Biomarkers and Susceptibility Unit, Oncology Data Analytics Program

[7] Catalan Institute of Oncology (ICO),Colorectal Cancer Group, ONCOBELL Program

[8] L’Hospitalet de Llobregat,Department of Clinical Sciences, Faculty of Medicine

[9] Bellvitge Biomedical Research Institute (IDIBELL),Department of Medicine

[10] L’Hospitalet de Llobregat,Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine

[11] Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP),Department of Genetics

[12] University of Barcelona,Institute of Translational Medicine and Therapeutics

[13] Corporal Michael J. Crescenz VA Medical Center,Department of Medicine

[14] University of Pennsylvania Perelman School of Medicine,Stanford Cardiovascular Institute

[15] University of Pennsylvania,Nutrition and Metabolism Section, International Agency for Research on Cancer

[16] Perelman School of Medicine,Department of Medicine I

[17] University of Pennsylvania,Department of Public Health and Primary Care

[18] University of Pennsylvania,Department of Medicine and Epidemiology

[19] VA Palo Alto Epidemiology Research and Information Center for Genomics,Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital

[20] VA Palo Alto Health Care System,Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health

[21] Stanford University School of Medicine,Department of Laboratory Medicine and Pathology

[22] Stanford University School of Medicine,Department of Epidemiology and Biostatistics, School of Public Health

[23] World Health Organization,undefined

[24] University Hospital Dresden,undefined

[25] Technische Universität Dresden (TU Dresden),undefined

[26] University of Texas MD Anderson Cancer Center,undefined

[27] University of Cambridge,undefined

[28] University of Pittsburgh Medical Center,undefined

[29] University of Toronto,undefined

[30] The University of Melbourne,undefined

[31] Mayo Clinic Arizona,undefined

[32] Imperial College London,undefined

[33] St Mary’s Campus,undefined

来源：

Diabetologia | 2023年 / 66卷

关键词：

ABCC8; Breast cancer; Colorectal cancer; GLP1R; Glucose-lowering drug targets; Mendelian randomisation; PPARG; Prostate cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1481 / 1500

页数：19

共 50 条

[21] Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis
Marianne Benn
Frida Emanuelsson
Anne Tybjærg-Hansen
Børge G. Nordestgaard
Diabetologia, 2021, 64 : 1492 - 1503
[22] GENETICALLY PROXIED THERAPEUTIC INHIBITION OF ANTIHYPERTENSIVE DRUG TARGETS AND RISK OF SYSTEMIC LUPUS ERYTHEMATOSUS: A MENDELIAN RANDOMIZATION ANALYSIS
Song, S.
Wang, C.
Zhao, R.
Qiao, J.
Zhang, S. X.
Li, X.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1067 - 1067
[23] Genetically Proxied Antidiabetic Drug Target and Primary Open-Angle Glaucoma: A Mendelian Randomization Study
Tang, Kefu
Wang, Wenqiu
Chang, Weiteng
Wu, Xi
HEALTH SCIENCE REPORTS, 2024, 7 (10)
[24] Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study
Liu, Luyang
Sheng, Chao
Lyu, Zhangyan
Dai, Hongji
Chen, Kexin
FRONTIERS IN NUTRITION, 2021, 8
[25] Risk of cancer and use of glucose-lowering medications: The DIABMON project
Boyle, Peter
Boniol, Mathieu
Koechlin, Alice
Bota, Maria
Robertson, Chris
Skyler, Jay
Boll, Geremla
Rosenstock, Jullo
Autler, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[26] Genetically proxied IL-6 signaling and risk of Alzheimer's disease and lobar intracerebral hemorrhage: A drug target Mendelian randomization study
Myserlis, Evangelos Pavlos
Ray, Anushree
Anderson, Christopher D.
Georgakis, Marios K.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2024, 10 (03)
[27] Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study
Chan, Wing Ching
Liu, Lili
Bouras, Emmanouil
Zuber, Verena
Wen, Wanqing
Long, Jirong
Gill, Dipender
Murphy, Neil
Gunter, Marc J.
Assimes, Themistocles L.
Bujanda, Luis
Gruber, Stephen B.
Kury, Sebastien
Lynch, Brigid M.
Qu, Conghui
Thomas, Minta
White, Emily
Woods, Michael O.
Peters, Ulrike
Li, Christopher I.
Chan, Andrew T.
Brenner, Hermann
Tsilidis, Konstantinos K.
Zheng, Wei
BRITISH JOURNAL OF CANCER, 2025, 132 (01) : 103 - 110
[28] Genetically Proxied Therapeutic Effect of Metformin Use, Blood Pressure, and Hypertension's Risk: a Drug Target-Based Mendelian Randomization Study
Jiang, Junhong
Hu, Di
Zhang, Qi
Lin, Zenan
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2024, 17 (03) : 716 - 722
[29] Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes
Marjolein M. J. Zanders
Harm R. Haak
Myrthe P. P. van Herk-Sukel
Lonneke V. van de Poll-Franse
Jeffrey A. Johnson
Diabetologia, 2015, 58 : 951 - 960
[30] Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes
Zanders, Marjolein M. J.
Haak, Harm R.
van Herk-Sukel, Myrthe P. P.
van de Poll-Franse, Lonneke V.
Johnson, Jeffrey A.
DIABETOLOGIA, 2015, 58 (05) : 951 - 960

← 1 2 3 4 5 →